MOTIVATE, Study of Treating Hemophilia A With Inhibitors, Enrolls 1st US Patient
A first patient in the U.S. has enrolled in a multinational study to collect real-world data on different approaches in…
Articles by Forest Ray PhD
Survey Outlines Top Concerns Among Hemophilia Patients in Central Europe
Mobility problems, bleeding, pain, and uncertainly in daily life are the biggest challenges people with hemophilia are facing, according…
US Healthcare Costs Average 25 Times Higher for Hemophilia B
Healthcare costs can be 25 times higher for hemophilia B patients than for individuals who do not have a…
Swimming, Hydrotherapy Improve Functional Capacity, Study Shows
Both swimming and hydrotherapy can improve functional capacity in hemophilia patients, according to data from a recent study. Of…
Posture Exercises May Improve Joint Health in Children
Exercises to control posture could improve joint health in children with hemophilia and should form part of regular rehabilitation…
Immunoadsorption May Be Useful Add-on Therapy in Acquired Hemophilia
Immunoadsorption, or the selective removal of antibodies from the blood, might prove useful as an add-on treatment for patients with…
Great Attention Needed in Care of Women and Girls With Hemophilia
Although hemophilia treatments are generally effective, women and girls with this disease have specific medical challenges, such as excessive menstrual bleeding, that…
COVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA, CDC Say
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected…
UniQure Shares Long-term Data About AMT-061 and AMT-060 Gene Therapy Candidates
Two potential gene therapies — AMT-060 and AMT-061 (etranacogene dezaparvovec) — lead to safe and long-term increases in…
MarzAA on FDA Fast Track to Treat Hemophilia A or B With Inhibitors
The U.S. Food and Drug Administration (FDA) has granted fast track designation to marzeptacog alfa activated (MarzAA), a lab-made…